N/A
Completed N=330
Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication
Source: ClinicalTrials.gov NCT02541864 ↗Enrolled (actual)
330
Serious AEs
0.0%
Results posted
Aug 2017
Primary outcomePrimary: Number of Participants in Which H. Pylori Was Eradicated — 154; 154 participants
Summary
According the Maastricht IV consensus report publish in the Gut 2012, bismuth containing quadruple therapy was suggested to be the first choice for eradication therapy of Helicobacter pylori in the area with high clarithromycin resistance. Whether hybrid therapy or 14-day bismuth containing quadruple therapy can replace standard triple therapy as the recommended first-line treatment is unknown. The investigators compared the efficacy of 14-day hybrid therapy and 14-day bismuth containing quadruple therapy in first-line treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants in Which H. Pylori Was Eradicated |
154; 154 | — |
Eligibility Criteria
Inclusion Criteria
- Consecutive H pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis
Exclusion Criteria
- previous H pylori-eradication therapy
- ingestion of antibiotics or bismuth within the prior 4 weeks
- patients with allergic history to the medications used
- patients with previous gastric surgery
- the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)
- pregnant women
Data sourced from ClinicalTrials.gov (NCT02541864). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.